| Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript | 08/13 19:39 | seekingalpha.com |
| Panbela Provides Business Update and Reports Q2 2024 Financial Results | 08/13 16:10 | globenewswire.com |
| Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024 | 07/30 16:15 | globenewswire.com |
| Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification | 06/24 08:00 | globenewswire.com |
| Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts | 05/20 01:36 | https://www.defenseworld.net |
| Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript | 05/15 19:30 | seekingalpha.com |
| Panbela Provides Business Update and Reports Q1 2024 Financial Results | 05/15 16:10 | globenewswire.com |
| Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac | 05/06 08:00 | globenewswire.com |
| Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024 | 05/01 16:15 | globenewswire.com |
| Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week | 04/30 08:00 | globenewswire.com |